US healthtech firm Omega Ophthalmics is developing implanted lenses that would create a platform for augmented reality inside the human eye. The company, currently awaiting approval from FDA as well as European regulators, has successfully carried out a small-scale clinical trial over the past six months with no ill-effects. Co-founder Gary Wortz said the space could offer manufacturers the opportunity to add "different interactive sensors, drug delivery devices and the inclusion of augmented and virtual reality integration".
US healthtech firm Omega Ophthalmics is developing implanted lenses that would create a platform for augmented reality inside the human eye. The company, currently awaiting approval from the US Food and Drug Administration as well as European regulators, has successfully carried out a small-scale clinical trial over the past six months with no ill-effects. Co-founder Gary Wortz said the space could offer manufacturers the opportunity to add "different interactive sensors, drug delivery devices and the inclusion of augmented and virtual reality integration".